John Lee, MD
Radiation Oncology · San Francisco, CANPI 1316938657
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,734 of the $2,382 with a category attached, or 72.8%. 16 manufacturers reported payments, led by Stryker at 39.2% of the total. Reporting peaked in 2021 at $1,303 and has fallen 75.0% since, to $325 in 2025.
Across 24 payments — averaging $99.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$933
- Siemens Medical Solutions USA, Inc.$174
- AstraZeneca$170
- Elekta, Inc.$151
- Visionrt, Inc.$146
- Portola Pharmaceuticals, LLC$126
- plus $682 from 10 others
What the payments were for
- Travel & lodging$64927%
- Food & beverage$1,73473%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 7 | $933 |
| Siemens Medical Solutions USA, Inc. | 1 | $174 |
| AstraZeneca | 3 | $170 |
| Elekta, Inc. | 1 | $151 |
| Visionrt, Inc. | 1 | $146 |
| Portola Pharmaceuticals, LLC | 1 | $126 |
| Progenics Pharmaceuticals, Inc. | 1 | $125 |
| Puma Biotechnology, Inc. | 1 | $125 |
| Daiichi Sankyo Inc. | 1 | $120 |
| Biogen | 1 | $93 |
| Reflexion Medical, Inc. | 1 | $68 |
| Angiodynamics, Inc. | 1 | $54 |
| Regeneron Healthcare Solutions, Inc. | 1 | $38 |
| Coherus Oncology, Inc. | 1 | $25 |
| Sanofi | 1 | $19 |
| Lilly USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,382 in reported general payments places this provider in the 75th percentile of 627 radiation oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 62 | $913 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 34 | $458 |
| Levofloxacin | 11 | $40 |
| Promethazine Hcl | 11 | $20 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in San Francisco
- Felix FengSan Francisco$99K
- David KornguthSan Francisco$46K
- Steve BraunsteinSan Francisco$41K
- I Chow HsuSan Francisco$13K
- Rakesh PatelLos Gatos$1.3M
- Amir LavafPalm Springs$411K
- Albert ChangLos Angeles$290K
- Arya AminiDuarte$265K
- Rizwan NuraniApple Valley$220K
- Drew MoghanakiLos Angeles$183K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.